- Home
- SPRO vs SPEG Comparison
SPRO vs SPEG Comparison
Compare SPRO & SPEG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SPRO | SPEG |
|---|---|---|
| Founded | 2013 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 136.7M | 154.3M |
| IPO Year | 2017 | 2025 |
Fundamental Metrics
Financial Performance| Metric | SPRO | SPEG |
|---|---|---|
| Price | $2.39 | $10.09 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $5.00 | N/A |
| AVG Volume (30 Days) | ★ 241.0K | 14.0K |
| Earning Date | 11-13-2025 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $40,549,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.51 | $9.95 |
| 52 Week High | $3.22 | $11.03 |
Technical Indicators
Market Signals| Indicator | SPRO | SPEG |
|---|---|---|
| Relative Strength Index (RSI) | 49.39 | N/A |
| Support Level | $2.26 | N/A |
| Resistance Level | $2.66 | N/A |
| Average True Range (ATR) | 0.08 | 0.00 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 33.77 | 0.00 |
Price Performance
Historical ComparisonAbout SPRO Spero Therapeutics Inc.
Spero Therapeutics Inc is a clinical-stage biopharmaceutical firm. It focuses on identifying, developing, and commercializing novel treatments for MDR (Multi-drug-resistant) bacterial infections and rare diseases. The company's product candidate, tebipenem pivoxil hydrobromide or tebipenem HBr, is designed to be an oral carbapenem-class antibiotic for use in adults to treat MDR Gram-negative infections. It is also developing SPR720, a novel oral antibiotic designed for the treatment of a rare, orphan disease caused by pulmonary non-tuberculous mycobacterial infections, or NTM disease. Besides, it is also focused on SPR206, a next-generation polymyxin investigational product candidate being developed as an IV-administered medicine to treat MDR Gram-negative infections in the hospital.
About SPEG Silver Pegasus Acquisition Corp Class A Ordinary Shares
Silver Pegasus Acquisition Corp is a blank check company.